Association of plasma ortho-tyrosine/ para-tyrosine ratio with responsiveness of erythropoiesis-stimulating agent in dialyzed patients

Redox Report

Volumn 19, Issue 5, 2014, Pages 190-198

  Kun, Szilárd ^a   Mikolás, Esztella ^a   Molnár, Gergo A ^a   Sélley, Eszter ^a   Laczy, Boglárka ^a   Csiky, Botond ^a   Kovács, Tibor ^a   Wittmann, István ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Chronic; Darbepoetin alfa; Hydroxyl radical; Kidney failure; Oxidative stress

Indexed keywords

3 (2 HYDROXYPHENYL)ALANINE; ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PHENYLALANINE; PHOSPHATE; POTASSIUM; TRANSFERRIN; TRIACYLGLYCEROL; TYROSINE; 2-TYROSINE; ANTIANEMIC AGENT; BIOLOGICAL MARKER;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHRONIC PYELONEPHRITIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULOPATHY; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; ADULT; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; ERYTHROPOIESIS; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROGNOSIS; RENAL REPLACEMENT THERAPY;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; TYROSINE;

EID: 84903770345     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/1351000214Y.0000000090     Document Type: Article

References (31)

1. Van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008;4:47-57.
2. Bamgbola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 2012;27:195-205.
3. Locatelli F, Covic A, Macdougall IC, Wiecek A. ORAMA: a study to investigate EBPG impact on renal anaemia-design and baseline data. J Nephrol 2008;21:592-603.
4. KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease; 2012. Available at: http://www.kdigo. org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL. pdf
5. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesisstimulating agent hyporesponsiveness. Nephrology (Carlton) 2007;12:321-30.
6. Rossert J, Gassmann-Mayer C, Frei D, McClellanW. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794-800.
7. Abe M, Okada K, Soma M, Matsumoto K. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. Clin Nephrol 2011;75:49-58.
8. Rudich A, Kozlovsky N, Potashnik R, Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 1997;272:935-40.
9. Ceriello A. Oxidative stress and glycemic regulation. Metabolism 2000;49:27-9.
10. Stadtman ER, Berlett BS. Fenton chemistry-amino acid oxidation. J Biol Chem 1991;266:17201-11.
11. Galano A, Cruz-Torres A. OH radical reactions with phenylalanine in free and peptide forms. Org Biomol Chem 2008;6:732-8.
12. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18:1272-80.
13. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol 2002;15:336-41.
14. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16:335-40.
15. Molnár GA, Nemes V, Bíró Z, Ludány A, Wagner Z, Wittmann I. Accumulation of the hydroxyl free radical markers meta-, ortho-tyrosine and DOPA in cataractous lenses is accompanied by a lower protein and phenylalanine content of the watersoluble phase. Free Radic Res 2005;39:1359-66.
16. Molnár GA, Wagner Z, Markó L, Koszegi T, Mohás M, Kocsis B, et al. Urinary ortho-tyrosine excretion in diabetes mellitus and renal failure: evidence for hydroxyl radical production. Kidney Int 2005;68:2281-7.
17. Tóth P, Koller A, Pusch G, Bosnyák E, Szapáry L, Komoly S, et al. Microalbuminuria, indicated by total versus immunoreactive urinary albumin in acute ischemic stroke patients. J Stroke Cerebrovasc Dis 2011;20:510-6.
18. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011;106:383-9.
19. Vivekanadan-Giri A, Wang JH, Byun J, Pennathur S. Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage. Rev Endocr Metab Disord 2008;9:275-87.
20. Joniau M, Coudijzer K, De Cuyper M. Reaction of alphatubulin with iodotyrosines catalyzed by tubulin:tyrosine ligase: carboxy-terminal labeling of tubulin with [125I]monoiodotyrosine. Anal Biochem 1990;184:325-9.
21. Gurer-Orhan H, Ercal N, Mare S, Pennathur S, Orhan H, Heinecke JW. Misincorporation of free m-tyrosine into cellular proteins: a potential cytotoxic mechanism for oxidized amino acids. Biochem J 2006;395:277-84.
22. Ruggiero RA, Bruzzo J, Chiarella P, di Gianni P, Isturiz MA, Linskens S, et al. Tyrosine isomers mediate the classical phenomenon of concomitant tumor resistance. Cancer Res 2011;71: 7113-24.
23. Watowich SS. The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Investig Med 2011;59: 1067-72.
24. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005; 15:146-55.
25. Ihle JN, ThierfelderW, Teglund S, Stravapodis D, Wang D, Feng J, et al. Signaling by the cytokine receptor superfamily. Ann NY Acad Sci 1998;865:1-9.
26. Sharma P, Chakraborty R, Wang L, Tremblay ML, Kawahara T, Lambeth JD, et al. Redox regulation of interleukin-4 signaling. Immunity 2008;29:551-64.
27. Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JH, et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialyzed patients? Nephrol Dial Transplant 1998;13:2583-7.
28. McCullough PA, BarnhartHX, Inrig JK, ReddanD, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013;37:549-58.
29. Ruppert C, Deiss K, Herrmann S, Oezkur M, Gorski A, Weidemann F, et al. Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy. Proc Natl Acad Sci USA 2013;110:7440-5.
30. Hirayama A, Nagase S, Gotoh M, Ishizu T, Yoh K, Aoyagi K, et al. Reduced serum hydroxyl radical scavenging activity in erythropoietin therapy resistant renal anemia. Free Radic Res 2002; 36:1155-61.
31. Kato A, Odamaki M, Hishida A. Blood 8-hydroxy-2'-deoxyguanosine is associated with erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 2003;18:931-6.